In a new study published in Nature Metabolism, scientists at the University of Florida examined whether the popular joint‑health supplement glucosamine could affect the course of dementia. The research focused on adults with mild cognitive impairment—a condition that often precedes Alzheimer’s disease.
How the Study Was Conducted
The team analyzed thousands of medical records, comparing patients who reported taking glucosamine with those who did not. They also performed laboratory experiments on mice and examined brain tissue from both healthy donors and individuals diagnosed with Alzheimer’s.
Senior author Dr. Ramon Sun, a professor of biochemistry and molecular biology, explained that glucosamine is a natural building block used by the body to create sugar chains on proteins, a process called glycosylation. “The right amount is essential,” Sun said.
Key Findings
Among participants with mild cognitive impairment, glucosamine use did not change overall mortality, but it was associated with a 25% increase in the likelihood of progressing to full‑blown dementia. For those already diagnosed with dementia, glucosamine users showed higher mortality rates than comparable non‑users.
Laboratory mice without Alzheimer’s‑like disease did not develop excess sugar chains or memory deficits when given glucosamine. In contrast, mice engineered to mimic Alzheimer’s showed increased sugar‑chain buildup and poorer performance on memory tests after receiving the supplement.
What the Researchers Say
Dr. Sun cautioned that the study is observational and cannot prove causation. “Health records tell us what was documented, not everything a person took,” he noted, emphasizing that over‑the‑counter supplements are often missing from medical files, and dosage, brand, and consistency were not captured.
Neil Levin, senior nutrition education manager for Now, a glucosamine manufacturer, reiterated that glucosamine is a naturally occurring compound that supports cartilage health. He stressed that the supplement’s primary purpose is joint support, not brain health.
Implications for Seniors and Caregivers
Both researchers agree that the findings should be viewed as a safety signal rather than definitive proof of harm. Dr. Sun called for a well‑designed, double‑blind clinical trial to determine whether glucosamine truly accelerates cognitive decline in vulnerable populations.
In the meantime, physicians are urged to discuss supplement use with patients who have mild cognitive impairment or dementia. “If you or a family member has a diagnosis of cognitive impairment and takes glucosamine, it’s reasonable to bring it up at the next visit,” a doctor advised.
Takeaway
The study does not suggest that glucosamine is dangerous for the general public who use it for joint health, but it raises concerns for those already experiencing memory problems. Seniors and their families should consult healthcare providers before starting or stopping any supplement, especially when cognitive issues are present.
Original reporting: Fox News (HLL/CB) — read the source article.
